Early results, based on small numbers of patients in a Phase I trial, indicate unprecedented progress in the development of a pharmacological treatment of Alzheimer’s Disease. The drug Aducanumab appears to combat (and reverse) the build-up of amyloid protein in the brain, and shows signs of being able to preserve memory and thinking skills in patients.
Researchers are cautiously optimistic. Phase III trials are underway.
Parkinson, C. (2016). Alzheimer’s drug study gives ‘tantalising’ results. London: BBC Health News, August 31st 2016.
This relates to:
Full Text Link (Note: This article requires a suitable Athens password, a journal subscription or payment for access; it may be available to view freely online for a limited period).
Sevigny, J. Chiao, P. [and] Bussière, T. [et al] (2016). The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature. Vol.537, pp.50–56. August 31st 2016.